TransCon CNP Shows Sustained Lower Limb Alignment Improvement in Achondroplasia at Week 104
TransCon CNP sustained lower limb alignment improvement in achondroplasia through Week 104, with mean tibial-femoral angle reduction of 3.8...
Definium’s Phase 3 LSD Win Is Real. The Fracture It Exposed Is Bigger.
Definium's LSD trial hit p<0.0001 and a $700M raise. But credible voices are asking whether FDA's drug model can...
4DMT Completes 4FRONT-2 Enrollment for 4D-150 Gene Therapy in Wet AMD
4D Molecular Therapeutics completes enrollment in 4FRONT-2, a Phase 3 trial of 4D-150 gene therapy for wet AMD, four...
Genmab’s Epcoritamab Plus Lenalidomide Meets Phase 3 Goal in Relapsed DLBCL
Genmab's epcoritamab plus lenalidomide achieved a 60% risk reduction in Phase 3 relapsed DLBCL trial, beating standard chemotherapy.
Sobi’s Gout CRL Is a Third-Party Manufacturing Indictment — And the Industry Wrote the Script
FDA issued Sobi a CRL for NASP on June 26, 2026, citing third-party manufacturing failures. Here's the operational breakdown...
FDA Approves Roflumilast Cream for Plaque Psoriasis in Children Age 2+
FDA approves roflumilast cream for plaque psoriasis in children as young as age 2, offering a steroid-free topical option...
VR Plus Neurostimulation Just Cleared a Major Feasibility Hurdle. Now Comes the Hard Part.
A Nature Medicine feasibility trial combining immersive VR with synchronous neurostimulation hit enrollment and kinematic endpoints in stroke rehab....
What Icon’s $300M Microsoft Bet Means for the Sites Running Their Trials
Icon's enterprise-wide Microsoft Copilot deployment and $300M AI investment will reshape how CRAs monitor, query, and escalate — here's...
Benchmark Scores Don’t Break. Clinical Reality Does. The Health AI Readiness Illusion.
Nature Medicine's frontier AI evaluation exposes a dangerous gap: models acing medical benchmarks collapse under adversarial pressure, and the...
Ipsen Acquires Kartos Therapeutics for $450M to Develop Navtemadlin for Myelofibrosis
Ipsen acquires Kartos for navtemadlin for myelofibrosis, an MDM2 inhibitor designed to help ruxolitinib non-responders. Phase III data expected...